Last reviewed · How we verify
NCT04755738: MWA
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
Phase 2 trial testing Almonertinib plus microwave ablation in Advanced Non Small Cell Lung Cancer in 234 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | Qianfoshan Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 234 |
| Start date | 1 January 2022 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Almonertinib plus microwave ablation
Conditions studied
- Advanced Non Small Cell Lung Cancer — all drugs for Advanced Non Small Cell Lung Cancer →
Sponsor
Qianfoshan Hospital
Who can join
Adults 18 to 80, any sex, with Advanced Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y, Wang H, He C. · · 2021 · cited 26× · PMID 34661758 · DOI 10.1007/s00432-021-03828-8 -
Endoscopic Technologies for Peripheral Pulmonary Lesions: From Diagnosis to Therapy.
Fantin A, Manera M, Patruno V, Sartori G, et al · · 2023 · cited 12× · PMID 36836612 · DOI 10.3390/life13020254
Verify or expand the search:
- PubMed search for NCT04755738
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
- NCT05777603 — Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer · Phase 1 · recruiting
- NCT06107374 — Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG · Phase 2 · recruiting
- NCT06406166 — Lifei Xiaoji Wan in Treatment of Advanced NSCLC · NA · recruiting
- NCT04886401 — Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC · recruiting
Other Qianfoshan Hospital trials
Trials by the same sponsor.
- NCT05727618 — The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery · NA · suspended
- NCT06837831 — Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin · NA · recruiting
- NCT07260760 — Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke · not yet recruiting
- NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
- NCT07271849 — Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04755738 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qianfoshan Hospital
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04755738.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing